Grifols, a Spanish pharmaceutical company, is facing challenges regarding a potential takeover by Brookfield. The latter's offer values Grifols at €6.5 billion, or €10.50 per share. However, Grifols' Transaction Committee has deemed this valuation insufficient. In support of Brookfield's bid, Temasek and GIC have pledged €3 billion. Despite this backing, analysts remain skeptical, with 82% valuing Grifols above the proposed price. Recent trading saw Grifols' shares rise by 1.21% to €10.46, reflecting market uncertainty about the offer. Additionally, the Audiencia Nacional is set to investigate reports related to Grifols, further complicating the situation as Brookfield's bid appears to be cooling.